SEC Comment Letter 0000000000-22-012751 to Virax Biolabs Group Ltd (VRAX) (CIK 0001885827) (VRAX)
Virax Biolabs Group Ltd (VRAX) (CIK 0001885827)
Date: Nov. 25, 2022 · CIK: 0001885827 · Accession: 0000000000-22-012751
AI Filing Summary & Sentiment
File numbers found in text: 333-268486
Letter
United States securities and exchange commission logo November 25, 2022 James Foster Chief Executive Officer Virax Biolabs Group Limited 30 Broadwick Street London, W1F 8LX United Kingdom Re:Virax Biolabs Group Limited Registration Statement on Form F-1 Filed November 21, 2022 File No. 333-268486 Dear James Foster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lawrence S. Venick, Esq.
Show Raw Text
United States securities and exchange commission logo
November 25, 2022
James Foster
Chief Executive Officer
Virax Biolabs Group Limited
30 Broadwick Street
London, W1F 8LX
United Kingdom
Re:Virax Biolabs Group Limited
Registration Statement on Form F-1
Filed November 21, 2022
File No. 333-268486
Dear James Foster:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lawrence S. Venick, Esq.